Panacell believes stem cell therapy could be effective against Long COVID PharmaLive – PharmaLive
stemadminStem Cell ResearchNo comments

Panacell believes stem cell therapy could be effective against long COVID Published: Aug 11, 2022 By Mark Terry BioSpace South Korean biotech company Panacell Biotechbelievesit has a way totreat long COVID. Panacell is a research institute specializing in regenerative cell therapies using adipose-derived stem cells (ADSC). It plans to initiate a program to investigate the use of natural killer (NK) immune cells, exosomes and brown adipose-derived stem cells to treat long COVID. Long COVID, which goes by theofficial nameof post-acute sequelae of SARS-CoV-2 infection (PASC), is defined by a broad range of symptoms that persist at least four weeks after infection. According to the Mayo Clinic, one in four people aged 65 or older suffers from the aftereffects of COVID-19

Read more
PVM to Play Role in Research on New Patent-pending Method to Mass-produce Antitumor Cells to Treat Blood Diseases and Cancer – Purdue University
stemadminStem Cell ResearchNo comments

Friday, August 12, 2022 A Purdue University chemical engineer has improved upon traditional methods to produce off-the-shelf human immune cells that show strong antitumor activity, according to a paper published in the peer-reviewed journal Cell Reports. And future research plans include clinical trials involving the Purdue University College of Veterinary Medicine. Dr

Read more
Reprogramming the Brain’s Cleaning Crew to Mop Up Alzheimer’s Disease – Weill Cornell Medicine Newsroom
stemadminStem Cell ResearchNo comments

The discovery of how to shift damaged brain cells from a diseased state into a healthy one poses a new potential path to treating Alzheimers and other forms of dementia, according to a new collaborative study from researchers at UC San Francisco and Weill Cornell Medicine. The research focuses on microglia, cells that stabilize the brain by clearing out damaged neurons and the protein plaques often associated with dementia and other brain diseases. These cells are understudied, despite the fact that changes in them are known to play a significant role Alzheimer's and other brains diseases, said Dr. Martin Kampmann, associate professor at the Institute for Neurodegenerative Diseases in the UCSF Weill Institute for Neurosciences and co-senior author on the study, which appears Aug.

Read more
CAR T-Cell Treatment at Higher Doses Reveal Beneficial Survival Data Without Worry of Added Toxicity – Targeted Oncology
stemadminStem Cell ResearchNo comments

Tisagenlecleucel boosted survival rates in children with B-cell lymphoblastic leukemia. Further research will be planned to examine the data and analyze additional clinical variables. Higher doses of tisagenlecleucel (Kymriah), a chimeric antigen receptor (CAR) T-cell therapy, displayed better survival rates at 1 year for young patients compared with patients who received lower doses who have B-cell lymphoblastic leukemia (B-ALL). Doses remained within the FDA-approved dosing range.1 In the past, we did not have data to guide clinical decisions around commercial CAR T-cell dosing and didnt know if higher doses would affect toxicity and compromise outcomes, or support enhanced anti-leukemia effect, said Liora Schultz, MD, pediatric oncologist at the Stanford Children's Health, Lucile Packard Children's Hospital, and the studys lead author. This data has direct clinical applicability, as it supports use of higher dosing, as available, within the approved tisagenlecleucel dose range

Read more
Researchers discover two signaling pathways that are downregulated in human hearts after birth – News-Medical.Net
stemadminStem Cell ResearchNo comments

Published today in Stem Cell Reports, researchers from the University of Minnesota Medical School discovered two signaling pathways that are downregulated in human hearts after birth. These pathways, mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)AKT, lead to maturation of heart cells, allowing them to adapt functionally to their postnatal role. The researchers showed that manipulating these pathways enabled better outcomes in experiments to generate cardiac myocytes, the beating cells of the heart, in vitro from pluripotent stem cells

Read more
Cell Therapy Technologies Market worth $8.0 billion by 2027 – Exclusive Report by MarketsandMarkets – PR Newswire
stemadminStem Cell ResearchNo comments

CHICAGO, Aug. 3, 2022 /PRNewswire/ --Cell Therapy Technologies Marketis projected to grow from USD 4.0 billion in 2022 to USD 8.0 billion by 2027, at a CAGR of 14.6% from 2022 to 2027, according to a new report by MarketsandMarkets.Growth in the market can be attributed to number of cell therapy clinical trials related to cancer. Furthermore, increasing incidence of communicable diseases and the growing risk of pandemics are also expected to fuel the market growth

Read more

Theme: Illdy.